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Hemangiomas are the most common tumor of the liver and distinguishing them from
malignancy is important. This is a report of 3 hemangiomas in 2 patients that exhibit
transient washout of gadoxetate disodium (Eovist), relative to blood pool and liver paren-
chyma, a characteristic that is used to diagnose hepatocellular carcinoma in at-risk
patients. It is important to recognize that high-flow hemangiomas can exhibit transient
washout when using a small volume of injected contrast agent. This finding is unlikely to
be present on CT examinations because of the larger volume of contrast administered.
Copyright © 2016, the Authors. Published by Elsevier Inc. under copyright license from the
University of Washington. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Case report continuous peripheral enhancement in the early arterialThe first case is that of a 52-year-old man with chronic hep-
atitis C and a suspiciousmass on surveillance ultrasound. The
patient was asymptomatic, and his alpha-fetoprotein level
was within normal limits. Magnetic resonance imaging (MRI)
with gadoxetate disodium was performed for further evalua-
tion (Fig. 1) and dynamic 3-dimensional (3D) fat-saturated (FS)
fast-spoiled gradient-echo (FSGR) images were obtained
before and after the administration of contrast using bolus
tracking method triggered off the abdominal aorta at the
diaphragm. Images were obtained in the early arterial (time ¼
0 s), late arterial (time ¼ 15 s), and portal venous (time ¼ 47 s)
phases. These sequences show a 2.1-cm mass with rapidlared that no competing i
efferson.edu (D.J.S. Becke
blished by Elsevier Inc. u
ND license (http://creativphase and transient washout relative to both the liver pa-
renchyma and vessels during the portal venous phase. When
using the Liver Imaging Reporting and Data System (LI-RADS)
criteria, the combination of size greater than 2.0 cm, arterial
phase hyperenhancement, and washout appearance would
lead to categorization of LI-RADS 5, or definitely hepatocellu-
lar carcinoma (HCC). However, extremely high signal on the
T2-weighted images and apparent diffusion coefficient (ADC)
map favored hemangioma, which was confirmed by contrast-
enhanced ultrasound (Fig. 2) and stability on subsequent
examinations. All 3D FS FSGR images were obtained with a
time to repetition of 4.1 ms and time to echo of 2.0 ms. The
precontrast, early arterial phase, and late arterial phasenterests exist.
r-Weidman).
nder copyright license from the University of Washington. This is
ecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1 e Case #1, contrast-enhanced MRI of hepatic hemangioma. A 52-year-old man with chronic hepatitis C. MRI
demonstrates a 2.1-cm lobulated mass (A, arrow) in the right lobe of the liver with marked hyperintense signal on single-
shot fast spin-echo T2-weighted images (time to echo ¼ 210 ms, flip angle ¼ 90). The lesion is hypointense on precontrast
3D FS FSGR (B, arrow) and on postcontrast images demonstrates peripheral enhancement without distinct nodularity or
discontinuity in the early arterial phase (C, arrow) and complete enhancement of the lesion with marked perilesional
arterioportal shunting in the late arterial phase (D, arrow). The lesion demonstrates washout appearance on the portal
venous phase (E, arrow) compared with the relative hyperintensity of the main portal vein (E, short arrow). Image obtained
during the same volume acquisition as image E through the intrahepatic portal vein (F) again demonstrates relative
hyperintensity of the portal vessels and liver parenchyma to the lesion.
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venous phase images were obtained with a flip angle of 20.
The second case is that of a 71-year-old man with an
incidentally noted hepatic lesion seen on CT. MRI with
gadoxetate disodium was performed further evaluation
(Fig. 3) and dynamic 3D FS FSGR images were obtained
before and after the administration of contrast using a fixed
time delay. Images were obtained in the early arterial (time
¼ 18 s postinjection), late arterial (time ¼ 30 s postinjection),
and transitional phases (time ¼ 4 min postinjection). These
sequences show 2 subcentimeter masses that both avidly
enhance during the early arterial phase and demonstratehypointensity during the late arterial phase, relative to both
the surrounding parenchyma and blood vessels, that
resolved by the transitional phase. Using the LI-RADS
criteria, the combination of size under 1.0 cm, arterial
phase hyperenhancement, and washout appearance would
lead to a categorization of LI-RADS 4, or probably HCC.
However, as in the previous case, high signal on the
T2-weighted and ADC images favored hemangiomas, which
was confirmed by stability on subsequent examinations. All
3D FS FSGR images were obtained using the following
parameters: time to repetition ¼ 2.6 ms, time to echo ¼ 1.2
ms, flip angle ¼ 15.
Fig. 2 e Case #1, contrast-enhanced ultrasound confirming hepatic hemangioma. Contrast-enhanced ultrasound
demonstratesmicrobubbles aggregating to the lesion (A, arrow) 26 seconds after injection. Themicrobubbles do notwashout
and at 8 minutes and 46 seconds they remain within the lesion (B, arrow), supporting the diagnosis of a hemangioma.
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Hemangiomas are the most common liver tumor, incidentally
found on approximately 5-20% of routine radiologic examina-
tions [1,2]. Differentiating these benign liver lesions fromFig. 3 e Case #2, contrast-enhanced MRI of hepatic hemangiom
history with an incidentally noted focal hepatic lesion seen on
segment 8 with marked hyperintense signal on fast spinecho T
echo ¼ 92 ms), no additional lesion is visible. Precontrast 3D FS
(B, arrow) and an additional 0.6-cm hypointense mass at the per
have identical contrast enhancement features and demonstrate
arrows) and washout relative to surrounding hepatic parenchym
marked perilesional arterioportal shunting in both phases. Themalignant neoplasms is an important and common clinical
scenario. Hemangiomas have a characteristic appearance on
dynamic contrast-enhanced (DCE) CT and DCEMRIwhen using
a purely extracellular agent. They demonstrate initial discon-
tinuous peripheral globular enhancement with centripetal
filling, which expands and persists on delayed-phase imaging,s. A 71-year-old man without significant past medical
CT. MRI demonstrates a 0.8-cm mass (A, arrow) in hepatic
2-weighted images (time to repetition ¼ 10,000 ms; time to
FSGR images demonstrate that this mass is hypointense
iphery of segment 8 anterior (B, small arrow). These masses
complete rapid enhancement in the early arterial phase (C,
a and portal vein on the late arterial phase (D, arrows) with
washout resolves in the transitional phase (E).
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Fig. 4 e Case #1, relative signal intensities illustrating
hemangioma washout. Case #1, dynamic-contrast
enhancement curves with measurements taken in the early
arterial, late arterial, and portal venous phases. The Y-axis
represents relative signal intensity. The signal intensity of
the back muscles is relatively stable for these time points
and acts as an internal control. The signal intensity of the
aorta oscillates with decreased signal in the late arterial
phase when compared to the early arterial and portal
venous phases. The signal intensity of the hemangioma
also oscillates but temporally lags behind the aorta. The
signal intensity of both the liver parenchyma and splenic
vein steadily increase throughout this time period.
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greatly. Attenuation or signal intensity of the enhancing areas
should be similar to that of the aorta and other vessels on all
phases. DCE kinetics of the aorta is different for CT and MRI
owing to the difference in the length of the contrast bolus used.
CT uses a relatively long contrast bolus and as a result the first
pass of contrast does not have time to redistribute before
recirculation of contrast occurs. This leads to the characteristic
single peak of enhancement followed by a rapid decrease in
enhancement which equilibrates at a low level of enhance-
ment, which then gradually decreases [3,4]. MRI uses a rela-
tively short bolus of contrast, so the first pass of contrast
redistributes before recirculation of the contrast can occur. As a
result, there is a large first-pass peak, followed by a smaller
recirculation peak, followed by equilibration and a gradual
decline in signal [5,6]. The sequential enhancement of some
hemangiomas is sufficiently rapid that they enhance
completely during the arterial phase. These high-flow hem-
angiomas account for 16% of all hemangiomas and occurmuch
more frequently in smaller lesions, accounting for 42% of
hemangiomas <1 cm in diameter [7]. The characteristic DCE
MRI appearance of a high-flow hemangioma when using a
purely extracellular contrast agent is well-described and con-
sists of arterial-phase immediate homogeneous enhancement
with persistant hyperintense signal on the all later phases,
similar to those of blood vessels [8,9].
MRI characteristics of hemangiomas using hepatocyte-
specific gadolinium-based contrast agents have been
described as similar during the arterial and early venous
phases to those observed using purely extracellular space
agents [9e13], although caution has been recommended
regarding their enhancement in later phases. In 2009, Doo
et al. described the “pseudo washout” sign, whereby a high-
flow hemangioma demonstrates relatively decreasing signal
intensity during the transitional phase (about 3-5 min after
contrast agent injection) as the contrast agent distributes
from the vascular space into hepatocytes. This low signal
intensity of the hemangioma is not because of actual washout
of contrast relative to blood pool, as the hemangioma and
blood vessels maintain similar concentrations of contrast
agent, and their hypointensity is exaggerated by the increased
signal intensity of the surrounding liver and the more rapid
blood pool clearance of hepatocyte-specific agents [14]. Sub-
traction images will demonstrate that the hemangioma has
not actually washed out relative to blood vessels.
A separate phenomenon of transient washout during the
late arterial or portal venous phases, as a short bolus of
contrastmaterial circulates during its first pass after injection,
can theoretically occur but has not been previously docu-
mented. We report 3 high-flow hemangiomas that demon-
strated a transient phase where the concentration of a
contrast agent decreased below that of other vessels such as
portal vein. This is not expected to happen with CT because of
the prolonged bolus length and is more likely to be present
when a temporally short bolus is injected, such as with
gadoxetate disodium (Eovist) or potentially with more
concentrated low-volume purely extracellular agents such as
gadobutrol (Gadavist).
The 2014 version of LI-RADS addresses the use of hep-
atobiliary contrast agents [15]. According to the LI-RADSguidelines, when using gadoxetate disodium, washout should
be evaluated during the portal venous phase and not the
transitional phase (3-5 min after contrast agent injection). This
is because the transitional phase is a dynamic phase during
which both hepatocyte uptake and extracellular distribution
contribute to the enhancement pattern [16]. Hypointensity in
the transitional phase may be due hepatocyte uptake of the
surrounding parenchyma, and therefore is different from
washout appearance as described when using a purely extra-
cellular agent. This distinction is not applicable to gadobenate
(MultiHance), as hepatocyte uptakewith gadobenate is delayed
until later phases [16].
DCE images were not obtained during identical phases for
cases #1 and #2, because of the different MR imaging protocols
used at the 2 different institutions. The dynamic images for
case #1 were obtained in the early arterial, late arterial and
portal venous phases, and transient washout of the heman-
giomawas seen in the portal venous phase. The relative signal
intensities of the hemangioma, aorta, liver parenchyma,
splenic vein, and back muscles were measured during
dynamic enhancement and are presented in Figure 4. The
aorta demonstrates the typical DCE kinetics of a short bolus
injection, with a recirculation peak in the portal venous phase,
causing the aorta to have decreased signal intensity in the late
arterial phase when compared with the early arterial and
portal venous phases. This oscillating signal intensity also
occurred in the hemangioma, which temporally lagged behind
the aorta and showed decreased signal intensity in the portal
venous phase compared with the late arterial phase. From the
early arterial phase through the portal venous phase the
signal intensities of the liver parenchyma and splenic vein
continuously increased and in the portal venous phase the
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hemangioma indicating that the hemangioma experienced
true washout. In pseudo washout, the hemangioma would
have been hypointense to the liver parenchyma but isointense
to the splenic vein. The dynamic images for case #2 were ob-
tained in the early arterial and late arterial phases, with
transient washout seen in the late arterial phase.
Transient washout likely depends on several coexisting
factors. The bolus of contrast injected must be short and
rapid. Both patients received 10 cc of gadoxetate disodium,
injected at 1 cc per second for patient #1 and 2 cc per second
for patient #2, with a total injection time of only 5-10 seconds,
likely shorter than the circulation time and shorter than the
image acquisition. There must be rapid flow through the
hemangioma, so that a short bolus of contrast will not only
enter but also exit rapidly during its first pass. Time-of-flight
effects are a separate phenomenon that may cause the in-
tensity of a hemangioma to differ from that of nearby blood
vessels. For example, inflow of unsaturated blood into the
imaged volume between excitations may increase signal in-
tensity within the aorta, IVC, or occasionally the portal vein,
depending on the location of the imaged volume. This was not
the case in this situation, as demonstrated by the low signal
within the vessels on the unenhanced volumetric images.
Transient washout of a hemangioma is not common, as it
depends on a combination of factors, including extremely
rapid flow and a short duration bolus of contrast material. We
do not intend for our report to invalidate the recommendation
in LI-RADS 2014 that gadoxetate disodium portal venous
phase images can be used to determine washout and thereby
contribute to diagnosis of HCC. However, one must be cogni-
zant that high-flow hepatic hemangiomas can exhibit tran-
sient washout during the portal venous phase or late arterial
phase and carefully consider other features of hemangiomas
to prevent misdiagnosis of HCC in these cases. In particular,
extremely high signal on T2-weighted images, high ADC,
isointensity to blood vessels more than one minute after
contrast agent injection, and marked perilesional arterio-
portal shunting may suggest high-flow hemangioma as a
possible diagnosis. If necessary, further evaluation with
multiphasic MRI using extracellular space or blood-pool
contrast agent, multiphasic CT, or a contrast-enhanced ul-
trasound can be performed to prevent mistaking a high-flow
hemangioma for malignancy.r e f e r e n c e s
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